Table 2

Cellular distribution of heparan sulfate proteoglycans in normal ovaries and ovarian tumors

Staining intensityNormal ovaryBenign tumorBorderline tumorCarcinoma
Syndecan-1Epithelial cellsGrade 011 (100)4 (30)4 (40)68 (59)
Grade 11 (0)3 (40)4 (40)24 (20)
Grade 20 (0)1 (10)1 (10)15 (13)
Grade 30 (0)2 (20)1 (10)5 [3 NK] (7)
Stromal cellsGrade 011 (100)8 (70)5 (50)64 (56)
Grade 10 (0)2 (30)2 (20)18 (15)
Grade 20 (0)0 (0)3 (30)24 (20)
Grade 31 (0)0 (0)0 (0)7 [2 NK] (8)
Syndecan-2Epithelial cellsGrade 03 (100)10 (100)10 (100)64 (100)
Stromal cellsGrade 01 (0)0 (0)2 (20)6 (7)
Grade 11 (50)5 (50)4 (30)43 (75)
Grade 20 (25)3 (40)3 (50)13 (15)
Grade 31 (25)2 (10)1 (0)3 (3)
Syndecan-3Epithelial cellsGrade 03 (100)10 (100)10 (100)65 (100)
Stromal cellsGrade 00 (0)0 (0)0 (0)2 (0)
Grade 11 (50)3 (40)1 (10)13 (25)
Grade 21 (50)6 (60)9 (90)34 (55)
Grade 31 (0)1 (0)0 (0)16 (20)
Blood vesselsGrade 00 (0)0 (0)0 (0)9 (4)
Grade 11 (25)1 (0)2 (20)9 (15)
Grade 22 (50)7 (70)7 (70)24 (53)
Grade 31 (25)1 [1 NK] (10)1 (10)18 [5 NK] (28)
Syndecan-4Epithelial cellsGrade 01 (25)3 (30)2 (20)9 (11)
Grade 132 (75)76 (70)7 (70)38 (65)
Grade 20 (0)1 (0)1 (10)17 (22)
Grade 30 (0)0 (0)0 (0)1 (2)
Stromal cellsGrade 03 (100)10 (100)10 (100)64 (100); 1 grade 1
Glypican 1Epithelial cellsGrade 03 (100)10 (100)10 (100)65 (100)
Stromal cellsGrade 03 (50)3 (40)7 (70)30 (45)
Grade 10 (25)7 (60)1 (10)31 (48)
Grade 20 (25)0 (0)2 (20)3 (5)
Grade 30 (0)0 (0)0 (0)1 (2)
Blood vesselsGrade 02 [1 NK] (100)6 [4 NK] (100)7 [3 NK] (100)45 [16 NK] (100); 4 grade 1
PerlecanBasement membraneGrade 00 (0)0 (0)3 (20)44 (67)
Grade 11 (25)0 (0)3 (40)2 (3)
Grade 21 (75)5 (50)2 (20)11 (16)
Grade 31 (0)5 (50)2 (20)8 (14)
StromaGrade 00 (0)0 (0)0 (0)0 (0)
Grade 11 (50)3 (30)4 (40)11 (17)
Grade 21 (25)5 (50)3 (30)33 (52)
Grade 31 (25)2 (20)3 (30)21 (31)
Blood vesselGrade 00 (0)0 (0)0 (0)1 (2)
Grade 11 (25)1 (10)2 (10)3 (4)
Grade 21 (0)5 (60)4 (50)24 (44)
Grade 31 (75)4 (30)4 (40)36 [1 NK] (50)
  • NOTE. For syndecan-1, the numbers of patients in each group were as follows: normal ovary (n = 12), benign tumor (n = 10); borderline tumor (n = 10), and carcinoma (n = 115). For the other heparan sulfate proteoglycans, the numbers of patients in each group were as follows: normal ovary (n = 3), benign tumor (n = 10); borderline tumor (n = 10), and carcinoma (n = 65). Values in parentheses indicate percentage of patients.

  • Abbreviations: NK, not known.